Cognitive functioning and health-related quality of life in long-term anaplastic oligondendroglioma and oligoastrocytoma survivors from the EORTC 26951 study: second follow-up

Completed

• Conditions: oligondendroglioma/oligoastrocytoma; primary brain tumor; 10029211

• Registration Number: NL-OMON55406
• Lead Sponsor: Haaglanden Medisch Centrum

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Completion: 2020-12-04
• Last Update Posted: 15 April 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 12

Inclusion Criteria

Patients are eligible for participation if they meet the following criteria:
1) They are diagnosed with an anaplastic oligodendroglioma or oligoastrocytoma;
2) They are adults; over 18 years old;
3) They participated in EORTC 26951 study and the first follow-up study;
4) They have signed the informed consent form, or, when unable to decide, their
legal representative signed the informed consent form for their participation
and the use of their data., Proxies are eligible for participation if they meet
the following criteria:
1) The patient is not deemed able to participate (as judged by the treating
physician) due to a poor physical or mental condition;
2) The patient has given consent that the proxy may participate on his behalf;
3) In the situation that the patient is deemed unable to decide, the legal
representative of the patient has signed the informed consent form to
participate;
4) The proxy has signed the informed consent form stating he/she agrees to
participate;
5) They are adults; over 18 years old.

Exclusion Criteria

Patients are not considered eligible for study participation if:
1) They are not eligible for participating in the study according to the
treating physician, due to severe physical or mental impairments hampering
filling in the questionnaires or undergoing the cognitive tests;
2) They are unable to communicate adequately., Proxies are not considered
eligible for study participation if:
1) They are unable to communicate adequately;
2) The patient, or his/her legal representative, has not signed the informed
consent form for proxy participation;
3) They proxy him- or herself has not signed his/her own informed consent form.

Study & Design

• Study Type: Observational non invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>NCF, HRQoL, mood, fatigue, cognitive complaints and health care utilization.</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>Cerebral abnormalities: white matter intensities (WMI) and global cerebral<br /><br>atrophy (GCA) of the latest and earlyer MRI scans.</p><br>